Cogent Biosciences (COGT)
Develops bezuclastinib and other mutation-targeted therapies for mast-cell disease and cancer.
$31.37
vs last close−1.26 (−3.86%)
Something off on this page? Send us feedback.
Next report
Nov 6, 26
estimated · in 44 days
EPS estimate
−$0.57
Revenue estimate
$750.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.61−$0.52−$0.53−$0.50−$0.55−$0.53−$0.52Pending
Estimate−$0.59−$0.56−$0.55−$0.54−$0.51−$0.53−$0.55−$0.57
Surprise−3.4%+7.1%+3.6%+7.4%−7.8%0.0%+6.3%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————$1.7M$500$1.0K$750.0K
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2029 | $0.95 | — | — |
| Sep 2029 | $0.74 | — | — |
| Jun 2029 | $0.57 | — | — |
| Mar 2029 | $0.41 | — | — |
| Dec 2028 | $0.25 | — | — |
| Sep 2028 | $0.10 | — | — |
| Jun 2028 | −$0.05 | — | — |
| Mar 2028 | −$0.18 | — | — |
| Dec 2027 | −$0.11 | — | — |
| Sep 2027 | −$0.29 | — | — |
| Jun 2027 | −$0.39 | — | — |
| Mar 2027 | −$0.44 | — | — |
| Dec 2026 | −$0.56 | — | — |
| Nov 2026 | −$0.57 | — | — |
| Aug 2026 | −$0.55 | −$0.52 | +6.3% |
| May 2026 | −$0.53 | −$0.53 | 0.0% |
| Feb 2026 | −$0.51 | −$0.55 | −7.8% |
| Nov 2025 | −$0.54 | −$0.50 | +7.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Dec 2017 | |||
| Mar 2018 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Sep 2016 | |||
| Sep 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2029 | $0.95 | — | — | $428.0M | — | — | — |
| Sep 2029 | $0.74 | — | — | $366.9M | — | — | — |
| Jun 2029 | $0.57 | — | — | $319.8M | — | — | — |
| Mar 2029 | $0.41 | — | — | $284.3M | — | — | — |
| Dec 2028 | $0.25 | — | — | $243.2M | — | — | — |
| Sep 2028 | $0.10 | — | — | $193.7M | — | — | — |
| Jun 2028 | −$0.05 | — | — | $153.4M | — | — | — |
| Mar 2028 | −$0.18 | — | — | $118.5M | — | — | — |
| Dec 2027 | −$0.11 | — | — | $125.0M | — | — | — |
| Sep 2027 | −$0.29 | — | — | $76.7M | — | — | — |
| Jun 2027 | −$0.39 | — | — | $50.1M | — | — | — |
| Mar 2027 | −$0.44 | — | — | $36.9M | — | — | — |
| Dec 2026 | −$0.56 | — | — | $6.0M | — | — | — |
| Nov 6, 2026 | −$0.57 | — | — | $750.0K | — | — | — |
| Aug 10, 2026 | −$0.55 | −$0.52 | +6.3% | $1.0K | — | — | −2.0% |
| May 5, 2026 | −$0.53 | −$0.53 | 0.0% | $500 | — | — | +0.7% |
| Feb 17, 2026 | −$0.51 | −$0.55 | −7.8% | $1.7M | — | — | +3.0% |
| Nov 7, 2025 | −$0.54 | −$0.50 | +7.4% | — | — | — | +0.7% |
| Aug 5, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 25, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 7, 2024 | |||||||
| Feb 26, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 14, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 15, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 16, 2021 | |||||||
| May 12, 2021 | |||||||
| Mar 16, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 11, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 26, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 12, 2019 | |||||||
| May 13, 2019 | |||||||
| Mar 28, 2019 | |||||||
| Nov 12, 2018 | |||||||
| Aug 13, 2018 | |||||||
| May 14, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Mar 29, 2018 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Sep 30, 2016 | |||||||
| Sep 30, 2015 |